Relugolix?

Relugolix is an oral drug that acts as a GnRH (Gonadotropin-Releasing Hormone) receptor antagonist. It suppresses the pituitary release of LH and FSH, which in turn lowers sex hormone levels (testosterone in men; estrogen in women).

Key points

- Brand/name: Orgovyx (United States); generic name relugolix.
- Mechanism: GnRH receptor antagonist → rapid suppression of LH/FSH → decreased testosterone (androgen deprivation) in men.
- Primary approved use (US): Treatment of adult men with advanced prostate cancer as part of androgen deprivation therapy. It is an oral alternative to injectable LHRH agonists.
- Onset of action: Testosterone levels fall quickly after starting treatment (often to castration levels within days); this differs from GnRH agonists, which can cause a flare.
- Dosing (typical): Often given as a once-daily oral dose. For the US-approved indication, the labeled dose is commonly 40 mg once daily (follow the exact labeling for your indication and country).
- Advantages vs some alternatives: Being oral, it avoids injections. In clinical trials, relugolix has shown a lower risk of major cardiovascular events compared with some injectable GnRH agonists in men with prostate cancer.
- Common side effects: Hot flashes, sweating, fatigue, headache, diarrhea or constipation, nausea; decreased libido; joint/muscle discomfort.
- Important safety considerations:
- Long-term suppression of sex hormones can lead to bone mineral density loss and osteoporosis; monitor bone health and consider calcium/vitamin D and exercise as appropriate.
- Potential effects on liver enzymes; monitor liver function tests as recommended.
- Could cause mood changes, sleep disturbances, or weight changes.
- Not for use in pregnancy; not a treatment for women’s reproductive conditions unless specifically approved for that indication.
- Interactions:
- Metabolized by CYP enzymes (notably CYP3A4); strong CYP3A4 inhibitors or inducers can alter exposure.
- Use caution with other medications that affect hormone levels or cardiovascular risk.
- Monitoring:
- Testosterone levels to confirm castration-level suppression (in men with prostate cancer).
- Bone health if on long-term therapy.
- Liver function tests as indicated.
- Special populations: Dose adjustments may be needed in hepatic impairment; use in pregnancy or lactation is not appropriate.

What would you like to know next?
- Dosing details for a specific country or indication
- More about safety, interactions, or monitoring
- How relugolix compares to other therapies (e.g., leuprolide or degarelix) for a particular situation
- Patient-friendly summary or a quick guide

If you have a specific use case or country in mind, I can tailor the information.